[go: up one dir, main page]

DK1443967T3 - Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor - Google Patents

Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor

Info

Publication number
DK1443967T3
DK1443967T3 DK02787572T DK02787572T DK1443967T3 DK 1443967 T3 DK1443967 T3 DK 1443967T3 DK 02787572 T DK02787572 T DK 02787572T DK 02787572 T DK02787572 T DK 02787572T DK 1443967 T3 DK1443967 T3 DK 1443967T3
Authority
DK
Denmark
Prior art keywords
inhibitor
combination
cyclooxygenase
histone deacetylase
relates
Prior art date
Application number
DK02787572T
Other languages
Danish (da)
English (en)
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1443967T3 publication Critical patent/DK1443967T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK02787572T 2001-11-06 2002-11-05 Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor DK1443967T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33301601P 2001-11-06 2001-11-06
US41931402P 2002-10-17 2002-10-17
PCT/EP2002/012343 WO2003039599A1 (fr) 2001-11-06 2002-11-05 Combinaison d'inhibiteur de cyclooxigenase-2 /inhibiteur d'histone desacetylase

Publications (1)

Publication Number Publication Date
DK1443967T3 true DK1443967T3 (da) 2007-04-16

Family

ID=26988512

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02787572T DK1443967T3 (da) 2001-11-06 2002-11-05 Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor

Country Status (22)

Country Link
US (3) US7402603B2 (fr)
EP (1) EP1443967B1 (fr)
JP (1) JP4413614B2 (fr)
KR (1) KR100937064B1 (fr)
CN (1) CN100457183C (fr)
AT (1) ATE352319T1 (fr)
AU (1) AU2002351844B2 (fr)
BR (1) BR0213932A (fr)
CA (1) CA2461373A1 (fr)
CY (1) CY1106508T1 (fr)
DE (1) DE60217895T2 (fr)
DK (1) DK1443967T3 (fr)
ES (1) ES2280597T3 (fr)
HU (1) HUP0402370A3 (fr)
IL (2) IL160970A0 (fr)
MX (1) MXPA04004312A (fr)
NO (1) NO20042148L (fr)
NZ (1) NZ544689A (fr)
PL (1) PL205853B1 (fr)
PT (1) PT1443967E (fr)
RU (1) RU2311200C2 (fr)
WO (1) WO2003039599A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (fr) * 2003-03-17 2004-09-30 Takeda San Diego, Inc. Inhibiteurs d'histone deacetylase
AR043850A1 (es) * 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
CN1791396A (zh) * 2003-05-21 2006-06-21 诺瓦提斯公司 组蛋白脱乙酰基酶抑制剂与化疗剂的组合
EP1491188A1 (fr) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Utilisation topique de l'acide valproique pour traiter des maladies de la peau
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (fr) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
CN101014595A (zh) * 2004-08-11 2007-08-08 杏林制药株式会社 新型环状氨基苯甲酸衍生物
EP1824831A2 (fr) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
WO2008023438A1 (fr) * 2006-08-25 2008-02-28 Asahi Glass Co., Ltd. Procédé servant à produire du 1,2-dialcoxy-3-fluorobenzène
US7786330B2 (en) 2005-02-28 2010-08-31 Asahi Glass Company, Limited Process for producing 1,2-dialkoxy-3-fluorobenzene
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101263121A (zh) * 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
EP1743654A1 (fr) * 2005-07-15 2007-01-17 TopoTarget Germany AG Utilisation d'inhibiteurs d'histone déacetylase avec des composés AINS pour traiter le cancer et/ou les maladies inflammatoires
WO2007016136A2 (fr) * 2005-07-28 2007-02-08 Nitromed, Inc. Sels d'inhibiteurs selectifs de la cyclo-oxygenase-2 activant l'acide nitrique organique, compositions et methodes d'utilisation
EP1976835A2 (fr) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Inhibiteurs des histone desacetylases
MX2008015899A (es) 2006-06-12 2009-04-01 Novartis Ag Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h- indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida.
NZ572707A (en) 2006-06-12 2011-12-22 Novartis Ag Process for making N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide and starting materials therefor
AU2007257881B2 (en) 2006-06-12 2011-06-16 Secura Bio Inc. Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
WO2008002634A1 (fr) * 2006-06-28 2008-01-03 Novartis Ag Utilisation d'inhibiteurs de la hdac pour le traitement des lymphomes
CN101662939B (zh) 2007-02-06 2015-11-25 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯,它们的制备及用途
EP2491923A3 (fr) * 2007-02-15 2012-12-26 Novartis AG Combinaisons d'agents thérapeutiques pour traiter le cancer
AU2008307541B2 (en) 2007-10-01 2015-02-12 Lixte Biotechnology, Inc. HDAC inhibitors
EP2318005B1 (fr) 2008-08-01 2017-11-01 Lixte Biotechnology, Inc. Agents neuroprotecteurs pour la prévention et le traitement de maladies neurodégénératives
WO2010147612A1 (fr) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Procédés de modulation de la régulation cellulaire par inhibition de p53
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
JP6118965B2 (ja) * 2012-04-16 2017-04-26 トーアエイヨー株式会社 2環性化合物
CA2909160C (fr) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations d'oxabicycloheptanes et d'oxabicycloheptenes
KR20170124602A (ko) 2015-03-13 2017-11-10 포르마 세라퓨틱스 인크. Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
JP7246309B2 (ja) 2016-12-08 2023-03-27 リクスト・バイオテクノロジー,インコーポレイテッド 免疫応答を調節するためのオキサビシクロヘプタン
CN115108926B (zh) * 2022-04-02 2023-06-20 上海工程技术大学 一种用于制备厄达替尼的中间体化合物及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)

Also Published As

Publication number Publication date
DE60217895T2 (de) 2007-07-05
PL368539A1 (en) 2005-04-04
KR20050043744A (ko) 2005-05-11
US20090192211A1 (en) 2009-07-30
RU2311200C2 (ru) 2007-11-27
PT1443967E (pt) 2007-04-30
CN100457183C (zh) 2009-02-04
WO2003039599A1 (fr) 2003-05-15
US20080227845A1 (en) 2008-09-18
JP4413614B2 (ja) 2010-02-10
NO20042148L (no) 2004-08-04
KR100937064B1 (ko) 2010-01-15
ATE352319T1 (de) 2007-02-15
PL205853B1 (pl) 2010-06-30
CN1578674A (zh) 2005-02-09
BR0213932A (pt) 2004-08-31
IL160970A (en) 2010-06-30
EP1443967A1 (fr) 2004-08-11
RU2004117170A (ru) 2005-04-20
AU2002351844B2 (en) 2006-12-21
EP1443967B1 (fr) 2007-01-24
MXPA04004312A (es) 2005-05-16
ES2280597T3 (es) 2007-09-16
CA2461373A1 (fr) 2003-05-15
NZ544689A (en) 2007-08-31
JP2005510517A (ja) 2005-04-21
DE60217895D1 (en) 2007-03-15
IL160970A0 (en) 2004-08-31
US20050032899A1 (en) 2005-02-10
CY1106508T1 (el) 2012-01-25
HUP0402370A3 (en) 2008-04-28
US7402603B2 (en) 2008-07-22
HUP0402370A2 (hu) 2005-02-28

Similar Documents

Publication Publication Date Title
DK1443967T3 (da) Kombination af cyclooxygenase-2-inhibitor/histondeacetylaseinhibitor
MXPA05012464A (es) Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
EA200401471A1 (ru) Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
WO2005004803A3 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
ATE408601T1 (de) Fredericamycin-derivate
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
CY1109045T1 (el) Ρετινοειδη για τη θεραπεια του εμφυσηματος
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
ATE438618T1 (de) Inhibitoren von humanem adam-10
BRPI0408466A (pt) composições farmacêuticas de inibidores de cetp e uso dos referidos inibidores
BR9815596A (pt) Composto, composição farmacêutica, método de tratamento de doenças inflamatórias e método de tratamento de condição ou doença mediada por mmps e/ou tnf e/ou agrecanase
WO2007002836A3 (fr) Procedes et compositions pour la prevention et le traitement de maladie renale
WO2006063294A3 (fr) Nouveaux inhibiteurs de l'histone deacetylase permettant de traiter une maladie
ATE423102T1 (de) 4-substituirte-5-cyano-1h-pyrimidin-6-(th)iones als als gsk-3-hemmer
WO2002096870A3 (fr) Terpenoides derives de l'eponge et procedes d'utilisation
ATE453614T1 (de) Sphingolipiden
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
PL370459A1 (en) Substituted urea retinoid agonists ii
PT1594456E (pt) Utilização de uma composição contendo óxido de vitamina k1 ou um seu derivado para tratamento e/ou prevenção de lesões dermatológicas em mamíferos
ECSP045071A (es) Combinacion de inhibidor de ciclooxigenasa-2/inhibidor de desacetilasa de histona